Skip to main content
. 2018 Jan 22;131(16):1820–1832. doi: 10.1182/blood-2017-11-817296

Table 1.

Baseline patient characteristics

Variable Patients with treatment-naïve disease Patients with relapsed/refractory disease Total
Patients, n 102 186 288
Median age (range), y 67 (41-83) 62 (33-85) 65 (33-85)
Sex, n (%)
 Female 40 (39) 49 (26) 89 (31)
 Male 62 (61) 137 (74) 199 (69)
Binet stage, n (%)
 A 32 (31) 61 (33) 93 (32)
 B 36 (35) 71 (38) 107 (37)
 C 32 (31) 52 (28) 84 (29)
 Unknown 2 (3) 2 (1) 4 (2)
ECOG performance score, n (%)
 0 38 (37) 54 (29) 92 (32)
 1 59 (58) 123 (66) 182 (63)
 2 4 (4) 6 (3) 10 (3)
 Unknown 1 (1) 3 (2) 4 (2)
IGHV status, n (%)
 Unmutated 51 (50) 135 (73) 186 (65)
 Mutated 38 (37) 33 (18) 71 (25)
 Unknown 13 (13) 18 (9) 31 (10)
Hierarchical model by FISH, n (%)
 Del(17p) 9 (9) 33 (18) 42 (15)
 Del(11q) 23 (23) 45 (24) 68 (24)
 Tri(12) 20 (20) 25 (13) 45 (16)
 Del(13p) 29 (28) 40 (22) 69 (24)
 None 17 (17) 28 (15) 45 (16)
Conventional karyotyping, n (%)
 <3 aberrations 93 (91) 149 (80) 242 (84)
 ≥3 aberrations (complex) 9 (9) 37 (20) 46 (16)
Median baseline laboratory values (range)
 White blood cell count, 109/L 79.35 (4.9-244.6) 31.45 (1.9-243.9) 45.85 (1.9-244.6)
 Hemoglobin level, g/dL 12.2 (8.9-16.4) 12.55 (8.2-16.5) 12.4 (8.2-16.5)
 Platelet count, 109/L 147.5 (45-464) 119.5 (22-494) 126.5 (22-494)
 β2M level, mg/L 3.9 (1.4-10.5) 4.1 (1.5-18.3) 4 (1.4-18.3)
ZAP-70 expression, n (%) 40 (40) 20 (11) 60 (21)